The global Systemic Inflammatory Response Syndrome Treatment market size is expected to reach over USD 17,259.5 million by 2027 from USD 9,811.0 million in 2019 with a registered CAGR of around 7.37% during forecast period 2020 to 2027. Growth of the market is driven mostly by an increase in the occurrence of SIRS and upsurge in knowledge about SIRS among healthcare professionals.
Developments in SIRS therapeutics are further brought in due to investment firms established in developed nations, who fund plentiful clinical development programs that possess the capability of formulating effective drugs. North America garnered major stake in the global systemic inflammatory response syndrome treatment market in 2019. This rapid growth is mainly credited to upsurge in the prevalence of SIRS and increase in knowledge about SIRS among healthcare professionals. Furthermore, upsurge in the geriatric population that is at high risk, surge in government initiatives
toward infectious & non-infectious diseases, a great number of players in North America concentrating on R&D activities to present technologically-advanced systemic inflammatory response syndrome treatments with improved designs push the market in the region.
Asia Pacific is anticipated to observe robust growth in the systemic inflammatory response syndrome treatment market. Asia Pacific is a comparatively untapped market than developed regions. Hence, the region offers enormous opportunities to market players. Intensification in the prevalence of SIRS, rise in knowledge about SIRS among healthcare professionals, development of the healthcare industry, and awareness in the region flourishes the growth of the SIRS treatment market in the region.
Europe gathered second-largest market followed by North America. Sophisticated healthcare infrastructure supplements the systemic inflammatory response syndrome treatment market in the region. The markets in the Middle East & Africa and Latin America are predictable to witness moderate growth in the upcoming years.
Systemic inflammatory response syndrome (SIRS) is an excessive body’s defensive response to a toxic source of stress to locate and then remove the endogenous or exogenous source of the insult such as infection, trauma, surgery, acute inflammation, ischemia or reperfusion, or malignancy. It includes the emergence of acute-phase reactants that are direct mediators of the subject’s widespread autonomic, endocrine, hematological and immunological alteration.
The dysregulated cytokine storm has the potential to trigger a major inflammatory cascade contributing to reversible or irreversible end-organ dysfunction and even death, even though the aim is protective. Sepsis is one type of systemic inflammatory response syndrome with a suspected cause of infection. Sepsis is considered extreme sepsis with one or more end-organ failures and septic shock with hemodynamic dysfunction despite intravascular volume repletion. Together, they represent a physiological pathway that eventually further deteriorates the equilibrium between pro and anti-inflammatory responses.
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. The virus is spreading globally, with people traveling much more frequently, living in more densely populated areas, and coming into contact with infected people. Various outbreaks occurred in the past, but did not reach a global pandemic level, as the novel coronavirus reaches. With this pandemic outbreak, the burden of both morbidity and mortality has increased exponentially and is leading to major disruptions in economic, social, and other aspects. In addition, the major burden has been fallen onto the healthcare sector and related inf restructure, even in the most developed countries with advanced and next level healthcare systems.
As per the WHO, the total cases of COVID-19 surpassed millions of cases as of many, 2020 worldwide. The outbreak has stepped into almost every country, globally, due to which the number of infected patients is rising, which is straining the countries’ healthcare ecosystem and resources. This is mainly on account of intensifying demand for healthcare facilities, workers; and most importantly medical equipment, devices, drugs, and researches. In almost every country, authorities are worried by continuously reducing availability of essential commodities, personal protective equipment (PPE), drugs/vaccines, testing kits, and others; and capacity to effectively manage the growing number of infected patients.
The recent dynamics of the entire Systemic Inflammatory Response Syndrome Treatment industry have changed due to the COVID-19 pandemic in 2020. Though there was a lockdown worldwide for few months, the unlock process in all the countries has begun. However, even during the lockdown the Systemic Inflammatory Response Syndrome Treatment industry saw a positive growth. The patients requiring urgent medical care were still being observed. There was a decrease in clinic visits and prescriptions in March and April. The Ophthalmology franchise was negatively impacted since patients were not visiting clinics to get physician-administered products. Expecting reimbursement was delayed in Europe based on various future decisions and approaches of different health authorities. Fluctuations in the supply & demand channels as a result of the strict lockdown measures imposed has caused disorder among several organizations. Digital solutions are in place to give patients access to online drug refills, disease education, and to enable more direct-to-patient services, Digital tools have been provided to sales associates to engage in real-time with physicians.
European countries like the UK, Germany, and Italy have swiftly adopted telemedicine. With regards to the uncertainty of revenue in the near term, companies are expected to face challenges even once the global economy rises from the pandemic.
No effective medication for the treatment of Systemic Inflammatory Response Syndrome is currently available on the market. Ono Pharmaceutical Co. in June 2002. Ltd. released Elaspol 100 for Injection; the world’s first Systemic Inflammatory Response Syndrome associated acute lung injury medicine. The net sales of the drug, however, decreased from US$ 33.3 million in 2013 to US$ 11.4 million in 2015. Therefore, new care options for Systemic Inflammatory Response Syndrome need to be created. In addition, in May 2003, Ono Pharmaceuticals Ltd. announced the termination of its Sivelestat exclusive license agreement with Eli Lilly and Company. Thus, Less Availability of Therapeutics for systemic inflammatory response syndrome hampers Market.
As dilemmas about the mass of sepsis increase in systemic inflammatory response syndrome, market players are working to develop effective drugs and therapeutics within the scope of innovation. CytoSorb®, a specific extracorporeal cytokine adsorber, is arising as a successful treatment to decrease inflammation and regulate the failure of essential organs such as the lungs, kidneys, heart and brain, amongst many other therapies. Biomarkers for early detection, treatment, and disposal of the condition have also been introduced as demand becomes more prominent for the initial-stage diagnosis of sepsis.
Apart from therapies, the development of numerous pipeline drugs is also led by extensive efforts supported by central and private funding. For example, Adrecizmab, which is considered efficient for the treatment of septic shock, was introduced by Adrenomed AG. The medication is also effective in preventing vascular damage and keeping ideal vascular functions intact. Thus, Therapeutics and pipeline drugs, driven by efficiency, are projected to maintain demand in the treatment market for systemic inflammatory response syndrome in the future.
Global Systemic Inflammatory Response Syndrome Treatment Market Revenue (USD Million) and Growth Rate Comparison by Product Type (2016-2027)
|Product Type||2016||2027||CAGR % (2020-2027)|
|Urinary Tract Infection (UTI)||740.7||1,348.10||5.74%|
Top Players contending in the Market:
- CytoSorbents Corporation
- Cardinal Health
- Asahi Kasei
- CHIESI Farmaceutici
- Smith & Nephew
Major Market Segments Covered:
By Product Type
- Urinary Tract Infection (UTI)
- Autoimmune Diseases
- Specialty Clinics
- Hospital & Ambulatory Surgical Centers
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa (MEA)
- North Africa
- South Africa
- Rest of Middle East & Africa
Report is Ready to Dispatch | If you need more information do not hesitate to ask our team @ firstname.lastname@example.org